Automated analyses

Advia LabCell Modular Automation Systems integrate clinical chemistry, immunodiagnostics, haematology, urinalysis, and other hospital and laboratory areas.

Photo: Automated analyses

The menus provide assays across virtually every area of disease management, and are supported by Bayer Diagnostics services, the manufacturer reports.

Advia LabCell is an open automation system that provides a comprehensive menu of automation and pre-analytical components as well as interfaces for recognized, high-volume analytical systems – Advia Centaur Immunoassay Systems, Advia Chemistry Systems, Advia Haematology Systems, Clinitek Atlas Automated Urine Chemistry Analyser, and Diagnostica Stago Star Coagulation Analyser – which can be added on for a customised automation solution that meets laboratories’ needs, Bayer adds. ‘Advia LabCell handles each sample as an individual, recognising precisely where that sample needs to go, then routing it for optimal efficiency.’ In addition, the system reduces the number of steps needed to sort, process, and archive samples, shortening the time to result. ‘Potential error is reduced by the minimised physical handling of samples prior to, in between, and following testing.’

The system connects seamlessly with existing IT systems, using plug-and-play to add or change instruments and components.


More on the subject:More on companies:

Related articles


Sponsored • Digital solutions for radiology

How to accelerate healthcare innovation in AI

Tapping the thriving Radiology AI ecosystem, Bayer recently announced three collaboration agreements for its digital platform, Calantic Digital Solutions, as well as an AI accelerator program.


Article •

Bayer in cancer collaboration

Finnish pharma company Orion and German healthcare giant Bayer have entered into an agreement for the development and commercialisation of a novel drug targeting prostate cancer.


Article •

Move to significantly strengthen position in consumer care

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion).

Related products

Subscribe to Newsletter